CDC Health Advisory: Patients Receiving Eculizumab at High Risk for Invasive Meningococcal Disease

Eculizumab (Soliris®) recipients have a 1,000 to 2,000-fold greater risk of invasive meningococcal disease compared to the general U.S. population. The Food and Drug Administration (FDA)-approved prescribing information for eculizumab includes a black box warning for increased risk of meningococcal disease, and the Advisory Committee on Immunization Practices (ACIP) recommends meningococcal vaccination for all patients receiving eculizumab. Recent data show that some patients receiving eculizumab who were vaccinated with the recommended meningococcal vaccines still developed meningococcal disease, most often from nongroupable Neisseria meningitidis, which rarely causes invasive disease in healthy individuals. Read the full advisory and recommendations.
 
 

Share this Post



 
 
 
 

Leave a Reply

The NCMS moderates this blog, so expect a slight delay in posting. Please include your full name and affiliation. We insist on respectful dialogue and reserve the right not to post remarks incompatible with our guidelines.

Your email address will not be published. Required fields are marked *